Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Quigel is a specialty biotechnology company focused on the development of high-performance hydrogel materials for medical devices and drug delivery. The company's core technology, the Quigel™ platform, consists of proprietary polymers that can be formulated to transition from a liquid to a solid gel state in response to physiological conditions. This technology is particularly well-suited for ophthalmic applications, such as sustained-release inserts for treating dry eye syndrome and glaucoma. By providing a stable, biocompatible matrix for therapeutic agents, Quigel aims to enhance the efficacy and safety of localized drug delivery. The company leverages its material science expertise to partner with pharmaceutical firms for the development of next-generation combination products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Quigel.